Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

Research output: Contribution to journalComment/debateResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Subbiah, Vivek ; Lassen, Ulrik ; Gasal, Eduard ; Burgess, Paul ; Wainberg, Zev A. / Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. In: Lancet Oncology. 2020 ; Vol. 21, No. 11. pp. e516.

Bibtex

@article{6c5e144fb1d44becbb0e780618939275,
title = "Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply",
author = "Vivek Subbiah and Ulrik Lassen and Eduard Gasal and Paul Burgess and Wainberg, {Zev A}",
year = "2020",
month = nov,
doi = "10.1016/S1470-2045(20)30625-2",
language = "English",
volume = "21",
pages = "e516",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "The/Lancet Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

AU - Subbiah, Vivek

AU - Lassen, Ulrik

AU - Gasal, Eduard

AU - Burgess, Paul

AU - Wainberg, Zev A

PY - 2020/11

Y1 - 2020/11

U2 - 10.1016/S1470-2045(20)30625-2

DO - 10.1016/S1470-2045(20)30625-2

M3 - Comment/debate

C2 - 33152307

VL - 21

SP - e516

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -

ID: 62313285